Close Menu

NEW YORK — PerkinElmer said on Monday that its first quarter 2020 revenues and EPS are expected to be below previous company estimates on softness in the China market.

The Waltham, Massachusetts-based firm had said in January during its fourth quarter and full-year 2019 earnings announcement that revenues for Q1 2020 would be $700 million, while EPS from continuing operations were anticipated to be $.33. Adjusted EPS from continuing operations were estimated at $.70.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.